Remicade

(Infliximab)

ApprovedMonoclonal antibody

Infliximab is used to treat inflammatory diseases like rheumatoid arthritis, Crohn's disease, and psoriasis by reducing the body's immune system overactivity that causes inflammation and pain.[2] Remicade is currently approved and in use across 26 indications[4].[1]

Remicade is one of 580 small molecule programs targeting Crohn's Disease. It is currently in Approved.

Indications

311

Total Trials

Active Trials

579

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Crohn's DiseaseNot yet recruiting

Ulcerative ColitisCompleted

InfliximabTerminated

HypertensionActive, not recruiting

ObesityActive, not recruiting

Psoriasis VulgarisUnknown

Immune System DiseaseUnknown

OsteomyelitisActive, not recruiting

Platelet AggregationActive, not recruiting

Ovarian ReserveActive, not recruiting

Crohn's DiseaseApproved

Not yet recruiting

Ulcerative ColitisApproved

Completed

InfliximabApproved

Terminated

HypertensionApproved

Active, not recruiting

ObesityApproved

Active, not recruiting

Psoriasis VulgarisPreclinical

Unknown

Immune System DiseasePreclinical

Unknown

OsteomyelitisPreclinical

Active, not recruiting

Platelet AggregationPreclinical

Active, not recruiting

Ovarian ReservePreclinical

Active, not recruiting

Showing 10 of 26 indications

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Remicade

Johnson & Johnson

Approved

1 2

Retatrutide

Eli Lilly

Phase 3

6 3

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

1 4

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

1 5

Zenagamtide

Novo Nordisk

Phase 3

3 6

Efsubaglutide Alfa

SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Phase 3

1 7

Survodutide

Boehringer Ingelheim

Phase 3

2 8

Aleniglipron

GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3

2 9

Semaglutide or Tirzepatide

NNational and Kapodistrian University of Athens

Phase 3

1 10

Avapro

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Crohn's Disease

NCT05813860

Q1 2027

Post-ApprovalRecruiting

Crohn's Disease

NCT05906576

Phase 2/3Recruiting

Infliximab

NCT05660746

Q4 2027

Phase 1/2Recruiting

Aneurysm

NCT02638701

Phase 1Recruiting

Infliximab

NCT02987686

Phase 2Not yet recruiting

Ulcerative Colitis

NCT07297069

Clinical

Trials by Indication[1]

Rheumatoid Arthritis29 trials

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)

Completed· Pfizer logo

Pfizer··NCT03885037·77 enrolled

Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00794898·19 enrolled

Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis

Completed·—·Phase 4·NCT02770794·211 enrolled

Show 26 more trials

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting·UUniversity of Nebraska·Phase 3·NCT03414502·400 enrolled

An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy

Completed· Roche logo

Roche··NCT01592292·90 enrolled

Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT01282528·85 enrolled

A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid Arthritis

Completed·CCentocor, Inc.·Phase 3·NCT00236028·607 enrolled

A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).

Completed· Pfizer logo

Pfizer·Phase 3·NCT02222493·650 enrolled

Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis

Unknown status·HHvidovre University Hospital·Phase 4·NCT00216177·112 enrolled

A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)

Withdrawn· Merck & Co. logo

Merck & Co.··NCT00724672

Real Life Dosing of Remicade for Rheumatoid Arthritis in Austria Monitored Over 9 Infusions (Study P03756)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00725621·516 enrolled

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis

Completed·CCentocor, Inc.·Phase 3·NCT00036374·123 enrolled

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

Terminated· Roche logo

Roche·Phase 2·NCT00808210·28 enrolled

Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

Completed· Amgen logo

Amgen·Phase 3·NCT02937701·558 enrolled

Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)

Completed·UUniversity of Leeds·Phase 4·NCT01308255·112 enrolled

Infliximab to Treat Children With Juvenile Rheumatoid Arthritis

Terminated·NNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 2·NCT00029042·48 enrolled

Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation

Terminated· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 4·NCT03100253·208 enrolled

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.

Completed·CCentocor, Inc.·Phase 3·NCT00036387·347 enrolled

An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis

Completed·CCentocor, Inc.·Phase 2·NCT00207714·172 enrolled

An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00896168·234 enrolled

An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1

Completed·CCelltrion·Phase 3·NCT01571219·302 enrolled

A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis

Completed·NNichi-Iko Pharmaceutical Co., Ltd.·Phase 3·NCT01927263·242 enrolled

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

Unknown status·GGeorgetown University·Phase 4·NCT01793519·290 enrolled

Pharmaco Kinetic Variability of Infliximab in Rheumatoid Arthritis

Completed·UUniversity Hospital, Tours··NCT00840957·84 enrolled

Infliximab for the Treatment of Early Rheumatoid Arthritis

Completed·NNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 2·NCT00006292·60 enrolled

SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.

Completed·JJulia Brown·Phase 4·NCT01295151·122 enrolled

RESTART C0168Z05 Rheumatoid Arthritis Study

Completed·CCentocor Ortho Biotech Services, L.L.C.·Phase 4·NCT00714493·203 enrolled

The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol

Completed·CCentocor Ortho Biotech Services, L.L.C.·Phase 4·NCT00246064·210 enrolled

A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01313520·61 enrolled

Ulcerative Colitis18 trials

A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01804166·1 enrolled

Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

Completed· Pfizer logo

Pfizer··NCT03884439·428 enrolled

Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00537316·242 enrolled

Show 15 more trials

Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

Active, not recruiting·AAlimentiv Inc.··NCT03765450·18 enrolled

Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00984568·28 enrolled

EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis

Completed·RRennes University Hospital·Phase 4·NCT03679546·151 enrolled

Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial

Not yet recruiting·—·Phase 2·NCT07297069·60 enrolled

Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 4·NCT05205603·438 enrolled

A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors

Completed· Roche logo

Roche·Phase 3·NCT02136069·397 enrolled

A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative Colitis

Completed·CCentocor, Inc.·Phase 3·NCT00096655·364 enrolled

TITRATE (inducTIon for acuTe ulceRATivE Colitis)

Terminated·—·Phase 4·NCT03937609·50 enrolled

A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative Colitis

Completed·CCentocor, Inc.·Phase 3·NCT00036439·364 enrolled

A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative Colitis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01551290·99 enrolled

Early Serum Infliximab Levels in Severe Ulcerative Colitis.

Completed·UUniversity of California, San Francisco·Phase 1·NCT01971814·11 enrolled

A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis

Completed·CCentocor, Inc.·Phase 3·NCT00336492·60 enrolled

Vedolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab

Not yet recruiting·JJAROSLAW KIERKUS·Phase 3·NCT06614387·60 enrolled

Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis

Unknown status·IIstituto Clinico Humanitas·Phase 4·NCT03151525·100 enrolled

European Safety Registry in Ulcerative Colitis (P04808)

Completed· Merck & Co. logo

Merck & Co.··NCT00705484·2,239 enrolled

Crohn's Disease18 trials

InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease

Recruiting·—·Phase 3·NCT06059989·158 enrolled

Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease

Recruiting·EErasmus Medical Center·Phase 4·NCT05552287·50 enrolled

HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease

Not yet recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 4·NCT05813860·976 enrolled

Show 15 more trials

A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease

Completed·JJohnson & Johnson (China) Investment Ltd.··NCT04312659·38 enrolled

Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)

Completed·—··NCT04131504·239 enrolled

Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

Recruiting·TTaizhou Mabtech Pharmaceutical Co.,Ltd·Phase 4·NCT05906576·30 enrolled

Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)

Completed· Merck & Co. logo

Merck & Co.··NCT01349920·15 enrolled

Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease

Not yet recruiting·CChinese Medical Association·Phase 4·NCT07417696·400 enrolled

N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·N/A·NCT04761952·236 enrolled

Association of Breg and Treg With the Clinical Effects of Infliximab in the Treatment of Patients With Crohn's Disease

Completed·SSecond Affiliated Hospital of Wenzhou Medical University··NCT04272788·32 enrolled

Regulatory T-cells and Crohn's Disease

Completed·HHvidovre University Hospital··NCT02060318·47 enrolled

Stop Infliximab in Patients With Crohn's Disease

Completed·GGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives·Phase 3·NCT00571337·126 enrolled

Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy

Completed·SSamsung Medical Center·Phase 3·NCT01661257·20 enrolled

Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery

Completed·UUniversity of Pittsburgh·Phase 4·NCT00688636·24 enrolled

Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00724958·348 enrolled

Treatment and Fate in Fistulizing Crohn's Disease in a Pediatric Population

Unknown status·—··NCT05759104·40 enrolled

Top-down Infliximab Study in Kids With Crohn's Disease

Completed·EErasmus Medical Center·Phase 4·NCT02517684·100 enrolled

Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00796250·9 enrolled

Psoriasis16 trials

Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00686686·23 enrolled

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Completed· Pfizer logo

Pfizer··NCT03885089·10 enrolled

Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)

Completed· Merck & Co. logo

Merck & Co.··NCT00725452·26 enrolled

Show 13 more trials

Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00833053·39 enrolled

A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis

Completed·CCentocor, Inc.·Phase 3·NCT00106847·683 enrolled

A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01177800·129 enrolled

Safety and Efficacy of Infliximab in Palmoplantar Psoriasis

Completed·IInnovaderm Research Inc.·Phase 3·NCT00629772·24 enrolled

Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00254982·593 enrolled

The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00251641·868 enrolled

A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis

Completed·CCentocor, Inc.·Phase 2·NCT00230529·249 enrolled

Assessment of Long-Term Infliximab for Psoriasis (P05319)

Completed· Merck & Co. logo

Merck & Co.··NCT00779675·660 enrolled

A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00687362·22 enrolled

Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00358670·441 enrolled

A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00687401·215 enrolled

A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00686595·48 enrolled

A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis

Completed·CCentocor, Inc.·Phase 3·NCT00106834·378 enrolled

Infliximab16 trials

Safety of Reduced Infliximab Infusion Time

Completed·WWashington University School of Medicine·Phase 4·NCT05340764·96 enrolled

A Long-term Safety Study of Infliximab (Remicade)

Completed·CCentocor, Inc.··NCT00261976·2,971 enrolled

Topical Infliximab for Sterile Corneal Melt

Recruiting·—·Phase 1·NCT02987686·12 enrolled

Show 13 more trials

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Withdrawn·—·Phase 1/2·NCT02126020

Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT00521924·8 enrolled

Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)

Terminated· Merck & Co. logo

Merck & Co.·Phase 4·NCT00686894·7 enrolled

The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety

Completed·TTaizhou Mabtech Pharmaceutical Co.,Ltd·Phase 1·NCT04779892·90 enrolled

The HAM Infliximab Study

Terminated·IImperial College London·Phase 2·NCT00823641·3 enrolled

Precise Infliximab Exposure and Pharmacodynamic Control

Recruiting·—·Phase 2/3·NCT05660746·180 enrolled

RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT00307593·20 enrolled

Beryllium Infliximab Study: Clinical Interventional Trial

Terminated·—·Phase 1/2·NCT00111917·13 enrolled

Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients

Withdrawn·—·Phase 4·NCT04530877

Infliximab Accelerated Induction in Moderate to Severe Pediatric UC

Terminated·SSchneider Children's Medical Center, Israel·N/A·NCT03209232·10 enrolled

Infliximab Biosimilar in Takayasu's Arteritis

Unknown status·OOspedale San Raffaele··NCT03192878·30 enrolled

Infliximab Top-down in Pediatric Crohn

Terminated·EErasmus Medical Center·Phase 4·NCT01880307·13 enrolled

Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies

Completed·HHospital General de Mexico·Phase 2/3·NCT00591201·26 enrolled

61 more indications

Ankylosing Spondylitis10 trials

Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis

Completed·AAssociation de Recherche Clinique en Rhumatologie·Phase 3·NCT00439283·240 enrolled

Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis

Completed·BBiocad·Phase 1·NCT02359903·90 enrolled

Infliximab and Methotrexate in Ankylosing Spondylitis

Completed·UUniversity Hospital, Tours·Phase 4·NCT00507403·30 enrolled

Show 7 more trials

Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Unknown status·JJagiellonian University·Phase 4·NCT02132234·100 enrolled

Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 4·NCT01148901

Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00202865·76 enrolled

A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.

Completed·CCentocor, Inc.·Phase 3·NCT00207701·279 enrolled

Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00725543·358 enrolled

Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00818168·320 enrolled

Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing Spondylitis

Completed·GGu Jieruo·Phase 4·NCT00936143·70 enrolled

Inflammatory Bowel Disease10 trials

Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study

Active, not recruiting·SShanghai 10th People's Hospital·N/A·NCT07149441·94 enrolled

Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

Completed·UUniversity Hospitals Cleveland Medical Center·N/A·NCT00791557·2 enrolled

Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT04982172·80 enrolled

Show 7 more trials

Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.

Completed·RRehab Werida·N/A·NCT05291039·56 enrolled

De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease

Enrolling by invitation·UUniversity Medical Center Groningen·Phase 4·NCT04646187·148 enrolled

An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT02566889·53 enrolled

Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease

Completed·—··NCT03445624·60 enrolled

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

Completed·HHikma Pharmaceuticals LLC··NCT03452501·157 enrolled

Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)

Completed·EErasmus Medical Center··NCT01971970·45 enrolled

Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

Active, not recruiting·—·Phase 4·NCT04835506·124 enrolled

Kawasaki Disease5 trials

Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease

Completed·UUniversity of California, San Diego·Phase 3·NCT00760435·196 enrolled

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

Completed·UUniversity of California, San Diego·Phase 1·NCT00271570·24 enrolled

KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)

Completed·UUniversity of California, San Diego·Phase 3·NCT03065244·105 enrolled

Show 2 more trials

Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease

Withdrawn·—·Phase 3·NCT04535518

Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial

Completed·FFudan University·Phase 3·NCT02298062·40 enrolled

COVID-195 trials

Infliximab in the Treatment of Patients With Severe COVID-19 Disease

Completed·JJena University Hospital·Phase 2·NCT04922827·9 enrolled

A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).

Completed·TTufts Medical Center·Phase 2·NCT04425538·17 enrolled

Immune Modulators for Treating COVID-19

Completed·DDaniel Benjamin·Phase 3·NCT04593940·1,971 enrolled

Show 2 more trials

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Unknown status·SSunnybrook Health Sciences Centre·Phase 3·NCT04330690·2,900 enrolled

Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome

Completed·—··NCT04734678·153 enrolled

Arthritis3 trials

The Chinese University of Hong Kong Early Arthritis Study

Completed·—·N/A·NCT00901550·40 enrolled

Seronegative Oligoarthritis of the Knee Study (SOKS)

Terminated·UUniversity of Leeds·Phase 2·NCT01216631·1 enrolled

Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00844805·158 enrolled

Safety and Efficacy3 trials

A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease

Completed·CCentocor, Inc.·Phase 3·NCT00207675·112 enrolled

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

Completed·FFlorida Academic Dermatology Centers·Phase 2·NCT00795574·38 enrolled

A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPD

Completed·CCentocor, Inc.·Phase 3·NCT00056264·234 enrolled

Psoriatic Arthritis3 trials

Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Unknown status·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT04610476·270 enrolled

A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis

Completed·CCentocor, Inc.·Phase 3·NCT00051623·70 enrolled

Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis

Completed·—·Phase 4·NCT00432406·40 enrolled

Colitis3 trials

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT04305145·42 enrolled

Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis

Recruiting·OOdense University Hospital·Phase 3·NCT05947669·195 enrolled

Anti-TNF Therapy for Refractory Colitis in Hospitalized Children

Completed·—··NCT02799615·38 enrolled

Diabetic Macular Edema2 trials

Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema

Unknown status·IIcahn School of Medicine at Mount Sinai·Phase 1/2·NCT00959725·10 enrolled

Treatment of Refractory Diabetic Macular Edema With Infliximab

Terminated·UUniversity of Athens·Phase 3·NCT00505947·12 enrolled

Inflammation2 trials

Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression

Completed·EEmory University·Phase 4·NCT03006393·42 enrolled

Inflammation-Induced CNS Glutamate Changes in Depression

Terminated·EEmory University·Phase 4·NCT03004443·22 enrolled

Efficacy and Safety2 trials

A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02505568·33 enrolled

Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection

Unknown status·GGenor Biopharma Co., Ltd.·Phase 3·NCT04178850·568 enrolled

Scleritis2 trials

Infliximab to Treat Non-Infectious Scleritis

Completed·NNational Eye Institute (NEI)·Phase 1·NCT00075075·5 enrolled

Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)

Withdrawn·HHospices Civils de Lyon·Phase 3·NCT03088293

Vasculitis2 trials

Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis

Terminated·—·Phase 2·NCT05168475·22 enrolled

Anti-Cytokine Therapy for Vasculitis

Completed·UUniversity Hospital Birmingham NHS Foundation Trust·Phase 2·NCT00753103·37 enrolled

Uveitic Macular Edema1 trial

Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema

Withdrawn·IIcahn School of Medicine at Mount Sinai·Phase 1/2·NCT00958906·10 enrolled

Cachexia1 trial

Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia

Completed·CCenter for Integrated Rehabilitation and Organ Failure Horn·Phase 2·NCT00244192·16 enrolled

Age-Related Macular Degeneration1 trial

Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration

Completed·NNational Eye Institute (NEI)·Phase 2·NCT00304954·13 enrolled

Maintenance Therapy1 trial

Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease

Unknown status·CChildren's Memorial Health Institute, Poland·Phase 3·NCT01559142·100 enrolled

Drug Monitoring1 trial

Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study

Unknown status·IIRCCS Burlo Garofolo·Phase 4·NCT05280405·86 enrolled

Myositis1 trial

Treatment With TNF Blockade, Infliximab, in Patients With Myositis

Completed·KKarolinska Institutet·Phase 2/3·NCT00443222

Inflammatory Response1 trial

TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.

Not yet recruiting·PPeking University Third Hospital·N/A·NCT07176754·208 enrolled

Cognitive Dysfunction1 trial

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

Recruiting·MMassachusetts General Hospital·Phase 2·NCT06136546·100 enrolled

Obesity1 trial

Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity

Completed·MMedical University of Graz·Phase 4·NCT00636142·9 enrolled

Perianal Crohn's Disease1 trial

Treatment of Perianal Crohn's Disease, Combining Medical and Surgical Treatment.

Terminated·SSheba Medical Center·N/A·NCT00252369

Kidney Transplant1 trial

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02495077·290 enrolled

Akkermansia Muciniphila1 trial

Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease

Not yet recruiting·CChinese Medical Association·Phase 4·NCT07415473·400 enrolled

Sarcoidosis1 trial

A Study of Infliximab in Patients With Sarcoidosis

Completed·CCentocor, Inc.·Phase 3·NCT00073437·139 enrolled

Eosinophilic Esophagitis1 trial

Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis

Completed·SSwiss EE Study Group·Phase 2·NCT00523354

Pemphigus Vulgaris1 trial

Use of Infliximab for the Treatment of Pemphigus Vulgaris

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00283712·20 enrolled

Osteomyelitis1 trial

CHronic Nonbacterial Osteomyelitis International Registry

Recruiting·SSeattle Children's Hospital··NCT04725422·2,000 enrolled

TED1 trial

Remicade Safety Line (Study P03236)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00748826·576 enrolled

Completed·UUniversity of Alberta·Phase 2·NCT00175266·12 enrolled

Autoimmune Disease1 trial

Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)

Completed·CCelltrion·Phase 1·NCT01220518·257 enrolled

Breast Cancer1 trial

Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

Terminated·JJonsson Comprehensive Cancer Center·Phase 2·NCT00112749·7 enrolled

Uveitis1 trial

A Clinical Trial of Infliximab for Childhood Uveitis

Unknown status·XXiaomin Zhang·Phase 4·NCT04150770·10 enrolled

Gene Polymorphism1 trial

A Study on the Relationship of Interleukin-7 Receptor Gene Polymorphisms With the Risk of Crohn's Disease Onset and the Efficacy of Infliximab

Completed·SSecond Affiliated Hospital of Wenzhou Medical University··NCT07263477·900 enrolled

Trial1 trial

Real-World Emulation of the SWEFOT Trial

Completed·KKarolinska Institutet··NCT05051137·509 enrolled

Atopic Dermatitis1 trial

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not yet recruiting·UUniversity of California, San Francisco·Phase 4·NCT07352566·10 enrolled

Crohn's Disease (CD)1 trial

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01190839·297 enrolled

Schizophrenia1 trial

Anti-Inflammatory Challenge in Schizophrenia

Recruiting·EEmory University·Phase 4·NCT05823532·20 enrolled

Biomarkers1 trial

Biomarkers to Predict and Monitor Response to Infliximab

Unknown status·MMassachusetts General Hospital··NCT04655729·120 enrolled

Lupus Nephritis1 trial

TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )

Terminated·MMedical University of Vienna·Phase 2/3·NCT00368264·1 enrolled

Acute Graft Versus Host Disease1 trial

GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease

Completed·EEmory University·Phase 1·NCT00228839

Hepatitis C1 trial

Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C

Completed·NNizar Zein·Phase 2·NCT00512278·146 enrolled

Major Depression1 trial

A Study of Infliximab for Treatment Resistant Major Depression

Completed·EEmory University·Phase 4·NCT00463580·60 enrolled

Induction Therapy1 trial

Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03371095·53 enrolled

Non-Small Cell Lung Cancer1 trial

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00040885·67 enrolled

Toxic Epidermal Necrolysis1 trial

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

Withdrawn·MMassachusetts Eye and Ear Infirmary·Phase 1/2·NCT01256489

Hermansky-Pudlak syndrome1 trial

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00514982

Hypertension1 trial

Effects of the TNF-alpha Inhibiton on Hemodynamic Parameters in Resistant Hypertension

Completed·UUniversity of Campinas, Brazil·Phase 4·NCT02743390·10 enrolled

Reactive Arthritis1 trial

New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis

Unknown status·—·Phase 2·NCT00244179·40 enrolled

Pilot Study1 trial

IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study

Completed·UUniversity of Alberta··NCT02847884·28 enrolled

Giant Cell Arteritis1 trial

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis

Terminated·CCentocor, Inc.·Phase 2·NCT00076726·44 enrolled

Cohort Study1 trial

A Cohort Study Comparing IFX to CS for Moderate to Severe UC

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University··NCT04879966·342 enrolled

Osteoarthritis1 trial

Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab

Completed·HHerbert Lindsley, MD·Phase 4·NCT01144143·16 enrolled

Polymyalgia Rheumatica1 trial

Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica

Unknown status·HHospital Universitario Marqués de Valdecilla·Phase 3·NCT01423591·23 enrolled

Efficacy1 trial

Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"

Unknown status·FFen Li·Phase 4·NCT02878161·240 enrolled

Aneurysm1 trial

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

Recruiting·UUniversity of California, San Francisco·Phase 1/2·NCT02638701·8 enrolled

Penetrating Keratoplasty1 trial

Topical Infliximab in Eyes With Penetrating Keratoplasty

Recruiting·—·Phase 1/2·NCT05180994·50 enrolled

Unspecified4 trials

Centocor Microarray Study of Patients

Completed·UUniversity of Rochester·Phase 4·NCT00462072·31 enrolled

A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417)

Completed· Merck & Co. logo

Merck & Co.··NCT00741104·363 enrolled

Post Marketing Surveillance of Remicade

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT00724529·938 enrolled

Show 1 more trial

Clinical and Molecular Phenotyping in IBD

Completed·UUniversity Hospital Schleswig-Holstein·N/A·NCT02694588·90 enrolled

Regulatory

FDA Approval Timeline[5]

Aug 24, 1998

REMICADE

NDA BLA103772

Aug 24, 1998

INFLIXIMAB

BLA BLA103772

Nov 10, 1999

REMICADE

NDA BLA103772

Dec 29, 2000

REMICADE

NDA BLA103772

Nov 27, 2001

REMICADE

NDA BLA103772

Feb 27, 2002

REMICADE

NDA BLA103772

Jun 28, 2002

REMICADE

NDA BLA103772

Apr 1, 2003

REMICADE

NDA BLA103772

Jul 3, 2003

REMICADE

NDA BLA103772

Jul 14, 2003

REMICADE

NDA BLA103772

Sep 3, 2003

REMICADE

NDA BLA103772

Sep 3, 2003

REMICADE

NDA BLA103772

Mar 10, 2004

REMICADE

NDA BLA103772

Jul 29, 2004

REMICADE

NDA BLA103772

Sep 29, 2004

REMICADE

NDA BLA103772

Oct 7, 2004

REMICADE

NDA BLA103772

Dec 17, 2004

REMICADE

NDA BLA103772

Dec 17, 2004

REMICADE

NDA BLA103772

Apr 5, 2005

REMICADE

NDA BLA103772

May 13, 2005

REMICADE

NDA BLA103772

Sep 15, 2005

REMICADE

NDA BLA103772

Mar 17, 2006

REMICADE

NDA BLA103772

May 19, 2006

REMICADE

NDA BLA103772

Aug 11, 2006

REMICADE

NDA BLA103772

Aug 11, 2006

REMICADE

NDA BLA103772

Sep 26, 2006

REMICADE

NDA BLA103772

Oct 13, 2006

REMICADE

NDA BLA103772

Dec 8, 2006

REMICADE

NDA BLA103772

Apr 19, 2007

REMICADE

NDA BLA103772

Jun 12, 2007

REMICADE

NDA BLA103772

May 19, 2008

REMICADE

NDA BLA103772

Aug 6, 2008

REMICADE

NDA BLA103772

Dec 22, 2008

REMICADE

NDA BLA103772

May 5, 2009

REMICADE

NDA BLA103772

Nov 18, 2009

REMICADE

NDA BLA103772

Apr 26, 2010

REMICADE

NDA BLA103772

Jul 29, 2010

REMICADE

NDA BLA103772

Oct 4, 2010

REMICADE

NDA BLA103772

Dec 28, 2010

REMICADE

NDA BLA103772

Feb 17, 2011

REMICADE

NDA BLA103772

Aug 1, 2011

REMICADE

NDA BLA103772

Sep 7, 2011

REMICADE

NDA BLA103772

Sep 23, 2011

REMICADE

NDA BLA103772

Oct 26, 2011

REMICADE

NDA BLA103772

Jun 28, 2012

REMICADE

NDA BLA103772

Mar 28, 2013

REMICADE

NDA BLA103772

Nov 6, 2013

REMICADE

NDA BLA103772

Jan 2, 2015

REMICADE

NDA BLA103772

Aug 27, 2015

REMICADE

NDA BLA103772

Oct 2, 2015

REMICADE

NDA BLA103772

Apr 21, 2017

RENFLEXIS

BLA BLA761054

Oct 25, 2017

REMICADE

NDA BLA103772

Jun 19, 2018

REMICADE

NDA BLA103772

May 14, 2020

REMICADE

NDA BLA103772

May 14, 2020

REMICADE

NDA BLA103772

May 14, 2020

REMICADE

NDA BLA103772

Oct 5, 2021

REMICADE

NDA BLA103772

Feb 28, 2025

REMICADE

NDA BLA103772

Sources

References

[1]
ClinicalTrials.gov — 311 trial records for Infliximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Remicade drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Infliximab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Infliximab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA BLA103772). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: TNF-Alpha Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Johnson & Johnson

Remicade

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Trials by Indication[1]

Rheumatoid Arthritis29 trials

Ulcerative Colitis18 trials

Crohn's Disease18 trials

Psoriasis16 trials

Infliximab16 trials

Ankylosing Spondylitis10 trials

Inflammatory Bowel Disease10 trials

Kawasaki Disease5 trials

COVID-195 trials

Arthritis3 trials

Safety and Efficacy3 trials

Psoriatic Arthritis3 trials

Colitis3 trials

Diabetic Macular Edema2 trials

Inflammation2 trials

Efficacy and Safety2 trials

Scleritis2 trials

Vasculitis2 trials

Uveitic Macular Edema1 trial

Cachexia1 trial

Age-Related Macular Degeneration1 trial

Maintenance Therapy1 trial

Drug Monitoring1 trial

Myositis1 trial

Inflammatory Response1 trial

Cognitive Dysfunction1 trial

Obesity1 trial

Perianal Crohn's Disease1 trial

Kidney Transplant1 trial

Akkermansia Muciniphila1 trial

Sarcoidosis1 trial

Eosinophilic Esophagitis1 trial

Pemphigus Vulgaris1 trial

Osteomyelitis1 trial

TED1 trial

Hematopoietic Stem Cell Transplantation1 trial

Dermatomyositis1 trial

Islet Transplantation1 trial

Autoimmune Disease1 trial

Breast Cancer1 trial

Uveitis1 trial

Gene Polymorphism1 trial

Trial1 trial

Atopic Dermatitis1 trial

Crohn's Disease (CD)1 trial

Schizophrenia1 trial

Biomarkers1 trial

Lupus Nephritis1 trial

Acute Graft Versus Host Disease1 trial

Hepatitis C1 trial

Major Depression1 trial

Induction Therapy1 trial

Non-Small Cell Lung Cancer1 trial

Toxic Epidermal Necrolysis1 trial

Hermansky-Pudlak syndrome1 trial

Hypertension1 trial

Reactive Arthritis1 trial

Pilot Study1 trial

Giant Cell Arteritis1 trial

Cohort Study1 trial

Osteoarthritis1 trial

Polymyalgia Rheumatica1 trial

Efficacy1 trial

Aneurysm1 trial

Penetrating Keratoplasty1 trial

Unspecified4 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News